Adipose Tissue Dysfunction in Nascent Metabolic Syndrome

Table 2

Novel adipokine concentrations.

Variable	Controls (𝑛=30)	MetS (𝑛=45)	𝑃 value; MetS versus control
hsCRP (mg/L)	1.3 (0.5, 4.0)	3.1 (1.6, 5.4)	0.006
HOMA-IR	1.1 (1.0, 2.8)	2.8 (1.9, 5.1)	0.0001
Plasma chemerin (ng/mL)	271 ± 53	366 ± 64	<0.0001
	𝑛=20	𝑛=37	*(0.0005)
SAT chemerin (ng/mg protein)	3.05 ± 0.94	3.94 ± 0.74	0.001
	𝑛=30	𝑛=45
Plasma omentin (ng/mL)	27 ± 14	16 ± 5	0.004
	𝑛=16	𝑛=16	*(0.03)
SAT omentin (ng/mg protein)	0.31 ± 0.09	0.22 ± 0.10	0.01
	𝑛=30	𝑛=45
Plasma resistin (ng/mL)	1.8 (1.5, 2.5)	2.4 (1.7, 3.1)	0.04
	𝑛=21	𝑛=31	*(0.07)
SAT resistin (ng/mg protein)	0.16 ± 0.06	0.17 ± 0.05	NS
	𝑛=30	𝑛=45
Plasma visfatin (ng/mL)	0.57 (0.38, 0.71)	0.59 (0.31, 0.96)	0.14
	𝑛=22	𝑛=36	*(0.13)
SAT visfatin (ng/mg protein)	0.17 ± 0.09	0.21 ± 0.1	NS
	𝑛=30	𝑛=45

 *(𝑃 value adjusted for age and BMI).
Results are presented as mean ± standard deviation or median (25th percentile and 75th percentile).